Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH). We performed a double-blind study of 7...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2021-01, Vol.160 (1), p.219-231.e1
Hauptverfasser:	Harrison, Stephen A., Neff, Guy, Guy, Cynthia D., Bashir, Mustafa R., Paredes, Angelo H., Frias, Juan P., Younes, Ziad, Trotter, James F., Gunn, Nadege T., Moussa, Sam E., Kohli, Anita, Nelson, Kristin, Gottwald, Mildred, Chang, William C.G., Yan, Andrew Z., DePaoli, Alex M., Ling, Lei, Lieu, Hsiao D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Lipid Metabolism NAFLD Nonalcoholic Fatty Liver Disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!